Anti-itga3 antibodies, activatable anti-itga3 antibodies, and methods of use thereof
AssigneeCytomX Therapeutics, Inc.
InventorsJason Gary Sagert, Jonathan Alexander Terrett, Luc Roland Desnoyers, Shweta Singh, Annie Yang Weaver
Life of this patent
Estimating the term…
Abstract
The invention relates generally to antibodies that bind ITGa3, activatable antibodies that specifically bind to ITGa3 and methods of making and using these anti-ITGa3 antibodies and anti-ITGa3 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
Claims87
An isolated antibody or an antigen binding fragment thereof (AB) that specifically binds to mammalian ITGa3, wherein the AB specifically binds human ITGa3 and cynomolgus monkey ITGa3.
An isolated antibody or an antigen binding fragment thereof (AB) that specifically binds to mammalian ITGa3, wherein the AB specifically binds human ITGa3 and cynomolgus monkey ITGa3, wherein the AB comprises a VH CDR1 comprising the amino acid sequence EYIIH (SEQ ID NO:
- 13);
- a VH CDR2 comprising the amino acid sequence WFYPESGSVKYNETFKG (SEQ ID NO:
- 14) or WFYPESGSVKYSETFKG (SEQ ID NO:
- 15) or WFYPESGSVKYNEAFKG (SEQ ID NO:
- 16) or WFYPESGSVKYNEGFKG (SEQ ID NO:
- 17);
- a VH CDR3 comprising the amino acid sequence HEERDYYGYYAMDY (SEQ ID NO:
- 18);
- a VL CDR1 comprising the amino acid sequence SASSSISSNYLH (SEQ ID NO:
- 19);
- a VL CDR2 comprising the amino acid sequence RTSNLA (SEQ ID NO:
- 20);
- and a VL CDR3 comprising the amino acid sequence QQGSSIPRFT (SEQ ID NO:
- 21), and wherein the AB is humanized.
(canceled)
An activatable antibody that, in an activated state, binds ITGa3 comprising:
- an antibody or an antigen binding fragment thereof (AB) that specifically binds to mammalian ITGa3, wherein the AB specifically binds human ITGa3 and cynomolgus monkey ITGa3;
- a masking moiety (MM) coupled to the AB that inhibits the binding of the AB to ITGa3 when the activatable antibody is in an uncleaved state;
- and
- a cleavable moiety (CM) coupled to the AB, wherein the CM is a polypeptide that functions as a substrate for a protease.
(canceled)
-15. (canceled)
-18. (canceled)
(canceled)
(canceled)
(canceled)
-34. (canceled)
An activatable antibody comprising an antibody or an antigen binding fragment thereof (AB) that specifically binds to mammalian ITGa3, a MM, and a CM, wherein the activatable antibody has one or more of the following characteristics selected from the group consisting of:
- (i) the activatable antibody comprises a heavy chain comprising an amino acid sequence of SEQ ID NO:
- 320;
- and a light chain sequence comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:
- 255, 257, 259, 261, 322, 324, 326, 328, 330, 332-359, and 364-391;
- (ii) the MM comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:
- 22-54, and the CM comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:
- 182-249 and 276-316;
- (iii) the AB comprises a VII CDR1 comprising the amino acid sequence EYIIH (SEQ ID NO:
- 13);
- a VII CDR2 comprising the amino acid sequence WFYPESGSVKYNETFKG (SEQ ID NO:
- 14) or WFYPESGSVKYSETFKG (SEQ ID NO:
- 15) or WFYPESGSVKYNEAFKG (SEQ ID NO:
- 16) or WFYPESGSVKYNEGFKG (SEQ ID NO:
- 17);
- a VII CDR3 comprising the amino acid sequence HEERDYYGYYAMDY (SEQ ID NO:
- 18);
- a VL CDR1 comprising the amino acid sequence SASSSISSNYLH (SEQ ID NO:
- 19);
- a VL CDR2 comprising the amino acid sequence RTSNLA (SEQ ID NO:
- 20);
- and a VL CDR3 comprising the amino acid sequence QQGSSIPRFT (SEQ ID NO:
- 21);
- (iv) the AB comprises a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:
- 3-10, and a light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:
- 11 and 12;
- and
- (v) the AB comprises a VII CDR1 comprising the amino acid sequence EYIIH (SEQ ID NO:
- 13);
- a VII CDR2 comprising the amino acid sequence WFYPESGSVKYNETFKG (SEQ ID NO:
- 14) or WFYPESGSVKYSETFKG (SEQ ID NO:
- 15) or WFYPESGSVKYNEAFKG (SEQ ID NO:
- 16) or WFYPESGSVKYNEGFKG (SEQ ID NO:
- 17);
- a VII CDR3 comprising the amino acid sequence HEERDYYGYYAMDY (SEQ ID NO:
- 18);
- a VL CDR1 comprising the amino acid sequence SASSSISSNYLH (SEQ ID NO:
- 19);
- a VL CDR2 comprising the amino acid sequence RTSNLA (SEQ ID NO:
- 20);
- and a VL CDR3 comprising the amino acid sequence QQGSSIPRFT (SEQ ID NO:
- 21), the MM comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:
- 22-54, and the CM comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:
- 182-249 and 276-316.
-39. (canceled)
(canceled)
-53. (canceled)
-60. (canceled)
A conjugated activatable antibody that, in an activated state, binds ITGa3 comprising:
- (a) an activatable antibody comprising:
- (i) an antibody or an antigen binding fragment thereof (AB) that specifically binds to mammalian ITGa3, wherein the AB specifically binds human ITGa3 and cynomolgus monkey ITGa3;
- (ii) a masking moiety (MM) coupled to the AB that inhibits the binding of the AB to ITGa3 when the activatable antibody is in an uncleaved state;
- and
- (iii) a cleavable moiety (CM) coupled to the AB, wherein the CM is a polypeptide that functions as a substrate for a protease;
- and
- (b) an agent conjugated to the AB.
(canceled)
(canceled)
(canceled)
(canceled)
-75. (canceled)
A conjugated antibody comprising:
- (a) an antibody or an antigen binding fragment thereof (AB) that specifically binds to mammalian ITGa3, wherein the AB comprises:
- (i) a VH CDR1 comprising the amino acid sequence EYIIH (SEQ ID NO:
- 13);
- a VH CDR2 comprising the amino acid sequence WFYPESGSVKYNETFKG (SEQ ID NO:
- 14) or WFYPESGSVKYSETFKG (SEQ ID NO:
- 15) or WFYPESGSVKYNEAFKG (SEQ ID NO:
- 16) or WFYPESGSVKYNEGFKG (SEQ ID NO:
- 17);
- a VH CDR3 comprising the amino acid sequence HEERDYYGYYAMDY (SEQ ID NO:
- 18);
- a VL CDR1 comprising the amino acid sequence SASSSISSNYLH (SEQ ID NO:
- 19);
- a VL CDR2 comprising the amino acid sequence RTSNLA (SEQ ID NO:
- 20);
- and a VL CDR3 comprising the amino acid sequence QQGSSIPRFT (SEQ ID NO:
- 21), or
- (ii) a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID 3-10, and a light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:
- 11 and 12;
- or
- (iii) a heavy chain comprising an amino acid sequence selected from the group consisting of SEQ ID NO:
- 320, and a light chain comprising an amino acid sequence selected from the group consisting of SEQ ID NO:
- 322;
- and
- (b) an agent conjugated to the AB, wherein the agent is selected from the group consisting of auristatin E, monomethyl auristatin F (MMAF), monomethyl auristatin E (MMAE), monomethyl auristatin D (MMAD), maytansinoid DM4, maytansinoid DM1, a calicheamicin, a pyrrolobenzodiazepine, a pyrrolobenzodiazepine dimer, and a duocarmycin.
A conjugated activatable antibody that, in an activated state, binds to ITGa3, comprising:
- (a) an activatable antibody comprising:
- (i) an antibody or an antigen binding fragment thereof (AB) that specifically binds to mammalian ITGa3, wherein the AB specifically binds human ITGa3 and cynomolgus monkey ITGa3;
- (ii) a masking moiety (MM) coupled to the AB that inhibits the binding of the AB to ITGa3 when the activatable antibody is in an uncleaved state;
- (iii) a cleavable moiety (CM) coupled to the AB, wherein the CM is a polypeptide that functions as a substrate for a protease;
- and
- (b) an agent conjugated to the AB,
- wherein the activatable antibody comprises:
- (i) a VH CDR1 comprising the amino acid sequence EYIIH (SEQ ID NO:
- 13);
- a VH CDR2 comprising the amino acid sequence WFYPESGSVKYNETFKG (SEQ ID NO:
- 14) or WFYPESGSVKYSETFKG (SEQ ID NO:
- 15) or WFYPESGSVKYNEAFKG (SEQ ID NO:
- 16) or WFYPESGSVKYNEGFKG (SEQ ID NO:
- 17);
- a VH CDR3 comprising the amino acid sequence HEERDYYGYYAMDY (SEQ ID NO:
- 18);
- a VL CDR1 comprising the amino acid sequence SASSSISSNYLH (SEQ ID NO:
- 19);
- a VL CDR2 comprising the amino acid sequence RTSNLA (SEQ ID NO:
- 20);
- and a VL CDR3 comprising the amino acid sequence QQGSSIPRFT (SEQ ID NO:
- 21), or
- (ii) a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:
- 3-10, and a light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:
- 11, 12, 396, 398, 400, 402, 404-431, 436, 438, 440, 442, and 444-471;
- or
- (iii) a heavy chain comprising an amino acid sequence selected from the group consisting of SEQ ID NO:
- 320, and a light chain comprising an amino acid sequence selected from the group consisting of SEQ ID NOS:
- 255, 257, 259, 261, 322, 324, 326, 328, 330, 332-359, and 364-391;
- and
- wherein the agent is selected from the group consisting of auristatin E, monomethyl auristatin F (MMAF), monomethyl auristatin E (MMAE), monomethyl auristatin D (MMAD), maytansinoid DM4, maytansinoid DM1, a calicheamicin, a pyrrolobenzodiazepine, a pyrrolobenzodiazepine dimer, and a duocarmycin.
(canceled)
(canceled)
A conjugated activatable antibody or conjugated antibody comprising:
- an antibody or antigen binding fragment thereof (AB) that, in an activated state, binds ITGa3;
- and
- a toxin conjugated to the AB via a linker,
- wherein the conjugated activatable antibody or the conjugated antibody comprises amino acid sequences, a linker, and a toxin selected from a single row in Table F, wherein for the given combination:
- (a) the AB comprises a heavy chain comprising the amino acid sequence of the heavy chain sequence or heavy chain variable domain sequence corresponding to the given combination in the single row listed in Table F,
- (b) the AB comprises a light chain comprising the amino acid sequence of the light chain sequence or light chain variable domain sequence corresponding to the given combination in the single row listed in Table F, and
- (c) the linker and the toxin comprise the linker and the toxin corresponding to the given combination in the single row listed in Table F.
Dependencies are inferred from the claim text.